Radiologist review versus group peer review of claimed responses in a phase II study on high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the EORTC Soft Tissue and Bone Sarcoma Group

被引:3
|
作者
Gwyther, SJ
Nielsen, OS
Judson, IR
van Glabbeke, M
Verweij, J
机构
[1] E Surrey Hosp, Surrey & Sussex NHS Trust, Surrey RH1 5RH, England
[2] Aarhus Univ Hosp, DK-800 Aarhus C, Denmark
[3] Inst Canc Res, CRC, Ctr Canc Therapeut, Sutton SM2 5NG, Surrey, England
[4] EORTC Data Ctr, B-1200 Brussels, Belgium
[5] Rotterdam Canc Inst, Daniel den Hoed Klin, NL-3008 AE Rotterdam, Netherlands
[6] Univ Hosp, NL-3008 AE Rotterdam, Netherlands
关键词
claimed responses; independent radiological; review; peer review; response rate;
D O I
10.1097/00001813-200007000-00003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The Soft Tissue and Bone Sarcoma Group (STBSG) of the EORTC ran a phase II study to assess the therapeutic activity of high-dose ifosfamide in patients with advanced soft tissue sarcomas by means of response rate (RR). Investigators claiming a response submitted the relevant chest radiographs (CXR) or scans to two other members of the STBSG for peer review. The reviewers completed a questionnaire indicating overall response or reasons for rejecting the claimed responses. An independent radiologist also reviewed the cases and he was blinded to the results of the peer review until the study was concluded. Twenty-two patients were reviewed by the radiologist and peer review, and the completed questionnaires were retrospectively reviewed. Two differences were noted, one partial responder (PR) was regarded as stable disease by the radiologist and one PR by peer review was determined a complete response by the radiologist. The radiologist found subsequent evidence of progressive disease in three patients who initially showed a PR, whilst the review group noted only one. This study suggests peer review in this tumor type is a satisfactory method of achieving an accurate, objective RR. [(C) 2000 Lippincott Williams & Wilkins].
引用
收藏
页码:433 / 437
页数:5
相关论文
共 50 条
  • [31] First-line doxorubicin and high-dose ifosfamide (DHI) in advanced soft tissue sarcoma (STS) patients. A phase II study of the Spanish Group for Research on Sarcomas (GEIS)
    Lopez-Pousa, A
    Montalar, J
    Buesa, J
    Maurel, J
    Martin, J
    Cassinello, J
    Sevilla, I
    de las Penas, R
    Cruz, J
    Balana, C
    ANNALS OF ONCOLOGY, 1998, 9 : 117 - 117
  • [32] Phase II study of neoadjuvant high-dose ifosfamide with concurrent radiotherapy followed by surgical resection in high -risk soft tissue sarcoma: A Spanish Group for Research on Sarcomas (GEIS) study
    Garcia del Muro, Xavier
    Lopez-Pousa, Antonio
    Jose Flor, Maria
    Redondo, Andres
    Cruz Jurado, Josefina
    Andres, Raquel
    Casado, Antonio
    Fra, Joaquin
    Lopez-Martin, Jose A.
    Maurel, Juan
    Maria Valverde, Claudia
    Gallego, Oscar
    Antonio Narvaez, Jose
    Bague, Silvia
    Sanjuan, Xavier
    Vinyals, Juan M.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [33] CYVADIC IN ADVANCED SOFT-TISSUE SARCOMA - A RANDOMIZED STUDY COMPARING 2 SCHEDULES - A STUDY OF THE EORTC SOFT-TISSUE AND BONE SARCOMA GROUP
    PINEDO, HM
    BRAMWELL, VHC
    MOURIDSEN, HT
    SOMERS, R
    VENDRIK, CPJ
    SANTORO, A
    BUESA, J
    WAGENER, T
    VANOOSTEROM, AT
    VANUNNIK, JAM
    SYLVESTER, R
    DEPAUW, M
    THOMAS, D
    BONADONNA, G
    CANCER, 1984, 53 (09) : 1825 - 1832
  • [34] Update of phase I study of imatinib (ST1571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group
    van Oosterom, AT
    Judson, IR
    Verweij, J
    Stroobants, S
    Dumez, H
    di Paola, ED
    Sciot, R
    Van Glabbeke, M
    Dimitrijevic, S
    Nielsen, OS
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S83 - S87
  • [35] Final results of a randomized phase II study of the EORTC Soft Tissue and Bone Sarcoma (STSBS) Group comparing two different ifosfamide (IF) regimens in chemotherapy untreated advanced soft tissue sarcoma (STS) patients (pts)
    van Oosterom, AT
    Krzemienlecki, K
    Nielsen, OS
    Judson, I
    Mouridsen, HT
    Svancarova, L
    Woll, P
    Spooner, D
    Hermans, C
    Van Glabbeke, M
    Verweij, J
    ANNALS OF ONCOLOGY, 1998, 9 : 115 - 115
  • [36] Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis
    Kollar, A.
    Jones, R. L.
    Stacchiotti, S.
    Gelderblom, H.
    Guida, M.
    Grignani, G.
    Steeghs, N.
    Safwat, A.
    Katz, D.
    Duffaud, F.
    Sleijfer, S.
    van der Graaf, W. T.
    Touati, N.
    Litiere, S.
    Marreaud, S.
    Gronchi, A.
    Kasper, B.
    ACTA ONCOLOGICA, 2017, 56 (01) : 88 - 92
  • [37] High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: Is it feasible?
    De Pas, T
    De Braud, F
    Orlando, L
    Nole, F
    Munzone, E
    Zampino, MG
    Fazio, N
    Aapro, MS
    Goldhirsch, A
    ANNALS OF ONCOLOGY, 1998, 9 (08) : 917 - 919
  • [38] Phase I study of sorafenib plus ifosfamide in patients with advanced soft tissue and bone sarcoma: A Spanish Group for Research on Sarcomas (GEIS) study.
    Garcia del Muro, X.
    Lopez-Pousa, A.
    Martin Broto, J.
    Cubedo, R.
    Jimenez Colomo, L.
    Gallego, O.
    Prevencio-Pulla, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [39] High-dose ifosfamide with hematopoietic growth factor support in advanced bone and soft tissue sarcomas
    Yalcin, B
    Pamir, A
    Buyukcelik, A
    Utkan, G
    Abulut, H
    Demirkazik, A
    Icli, F
    EXPERIMENTAL ONCOLOGY, 2004, 26 (04) : 320 - 325
  • [40] High-dose ifosfamide and doxorrubicin (HDI-DX) in advanced previously untreated soft tissue sarcoma (STS) patients.: A phase II study of the Spanish group for research on sarcomas (GEIS).
    Pousa, AL
    Buesa, JM
    Montalar, J
    Martín, J
    Maurel, J
    del Muro, JG
    de las Peñas, R
    Cruz, J
    Cassinello, J
    Sevilla, I
    Balaña, C
    Casado, A
    Bover, I
    Paredes, A
    Carles, J
    Poveda, A
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S88 - S88